April 22 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB ANNOUNCES TOPLINE RESULTS FROM PHASE 3 ARISE TRIAL EVALUATING COBENFY (XANOMELINE AND TROSPIUM CHLORIDE) AS AN ADJUNCTIVE TREATMENT TO ATYPICAL ANTIPSYCHOTICS IN ADULTS WITH SCHIZOPHRENIA
BRISTOL-MYERS SQUIBB CO - COBENFY DID NOT REACH STATISTICAL SIGNIFICANCE IN PHASE 3 TRIAL
BRISTOL-MYERS SQUIBB CO - COBENFY SAFETY AND TOLERABILITY CONSISTENT WITH PREVIOUS TRIALS
Source text: ID:nBw8K3lGVa
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。